Anxiety is highly prevalent in Parkinson's disease and negatively impacts quality of life yet
it frequently remains untreated and there have been no clinical trials dedicated to
evaluating the pharmacological treatment of anxiety in Parkinson's disease. Buspirone is
effective for the treatment of generalized anxiety disorder in the general and elderly
population. It is not known if it is effective for the treatment of anxiety in Parkinson's
disease. This is a single-center, placebo-controlled, double-blind design with participants
randomized with a 4:1 allocation ratio to flexible dosage buspirone (maximum dosage 30 mg
twice daily) or placebo for 12 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
University of Rochester
Collaborator:
Michael J. Fox Foundation for Parkinson's Research